


THE SIXTH SOUTH AFRICAN NATIONAL HIV PREVALENCE, INCIDENCE, AND BEHAVIOUR SURVEY (SABSSM VI)

20 YEARS OF STRATEGIC HIV AND PUBLIC HEALTH DATA

Launch of the key findings

27 November 2023





















OVERVIEW OF PRESENTATION



- Background about the SABSSM survey series
- Main objectives of the study
- Study methods
- Results
 - Response rates
 - National HIV prevalence
 - Viral load suppression
 - Progress towards 95-95-95 targets
 - Condom use
- Concluding remarks



















WAY BACK IN 2002



Expanded scope

Larger sample size


Increased biomarkers

Take all approach

Electronic data collection



Major source of information for measuring the progress of the implementation of the South African National Strategic Plan (NSP) for HIV, STIs and TB





















MAIN OBJECTIVES

To estimate at national, provincial and district levels (PEPFAR and NDoH priority):

- HIV prevalence (adults and children)
- Exposure to ART

Viral load suppression in HIV-infected individuals

To estimate at national level:

 HIV incidence (annualized rate of new HIV infections)



















STUDY METHODS

Geographic scope



- National level: 9 provinces
- District level: 27 PEPFAR and 6 National Department of Health priority districts

Study design and population * † † † †

- A cross-sectional, population-based household survey, using multistage stratified cluster random sampling
- The study design and methods are validated in the five previous surveys

Survey population ******



- Persons of all ages living in South Africa at the time of the survey
- All members of the selected households were invited to participate
- Data collection occurred over 15 months, from January 2022 to April 2023






















QUESTIONNAIRES

Household Questionnaire



Individual questionnaires /



- Questionnaire for parent/guardian of children aged 0 to 11 years
- Questionnaire for children aged 12 to 14 years
- Questionnaire for persons aged 15 years and older



















SPECIMEN COLLECTION



Dried blood spot (DBS) specimens collected by

- finger-prick
- heel-prick in infants < 24 months






















SPECIMEN TESTING





* Not reported in this presentation





*HIV Incidence

(> 2 years)

LAg assay/ RITA plus















WEIGHTING PROCEDURE

- Small area layer (SAL) (primary sampling unit) weights reflect the allocation of SALs according to the three stratification variables, namely race, province, and locality type.
- In each sampled SAL, a systematic random sample of 15 visiting points (VPs)
 was selected, with VPs in each SAL having the same base weight.
- SAL base weights were adjusted to correct for the invalid and unrealised SALs
- VP weights were computed as the counted number of VPs in the SAL, corrected proportionally for invalid VPs, and divided by the number of VPs participating in the survey.
- Final VP sampling weight was computed as the product of the SAL sampling weight and the VP sampling weight.
- Demographic and HIV-testing information for all household members within the responding SALs were gathered to calculate individual sample weights.
- These individual weights were further adjusted for questionnaire and HIVtesting non-response.
- The final individual weights were benchmarked against the 2022 census population by age, race, sex, and province.



















RESULTS





















RESPONSE RATES

- 29 447 VPs were approached, where 27 005 (91.7%) were valid.
- Of 27 005 valid households, 80.0% completed a household interview.
- Of the eligible 76 134 individuals, aged 0+ years and older, 94.1% were interviewed, and 62.7% provided blood for HIV and additional testing.
- Of the 30 718 eligible women, aged 15 years and older, 94.9% were interviewed, and 69.0% provided blood for HIV and additional testing.
- Of the 22 665 eligible men, aged 15 years and older, 90.6% were interviewed, and 60.8% provided blood for HIV and additional testing.




















UNDERSTANDING THE HIV EPIDEMIC























OVERALL HIV PREVALENCE, SOUTH AFRICA, 2017 AND 2022

- The overall national estimate for HIV prevalence for all ages in 2022 was 12.7% (95% CI: 12.0–13.4), translating to 7.8 million (95% CI: 7.2–8.4)
- The HIV prevalence was 1.3% lower than the estimate found in 2017, which was 14.0% (95%CI:13.2 14.8), translating to 7.9 million (95% CI: 7.2–8.6)
- This represents 107 000 fewer people living with HIV in 2022




















HIV PREVALENCE AMONG PEOPLE AGED 15+ BY PROVINCE, SOUTH AFRICA, 2022






















HIV PREVALENCE BY SEX AND AGE, SOUTH AFRICA, 2022



Age group (years)




















OVERALL HIV PREVALENCE AMONG MALES, SOUTH AFRICA, 2017 AND 2022






















OVERALL HIV PREVALENCE AMONG FEMALES, SOUTH AFRICA, 2017 AND 2022





















OVERALL HIV PREVALENCE BY AGE

SOUTH AFRICA, 2017 AND 2022

Age group (years)	2017		2022		
	HIV-positive (%)	Number of PLHIV	HIV-positive (%)	Number of PLHIV	
Total	14.0	7 917 000	12.7	7 810 000	
0–14	2.8	471 000	2.4	390 000	
15–24	7.8	754 000	5.2	533 000	
25–49	26.3	5 581 000	22.1	5 300 000	
50+	12.4	1 111 000	14.0	1 588 000	
15–49	20.6	6 335 000	17.0	5 833 000	
15+	18.7	7 446 000	16.3	7 420 000	




















HIV PREVALENCE AMONG 15 YEARS AND OLDER BY PROVINCE, SOUTH AFRICA, 2017 AND 2022



Province

■ 2017 **■** 2022




















VIRAL LOAD SUPPRESSION AMONG PEOPLE AGED 15+ LIVING WITH HIV BY PROVINCE, SOUTH AFRICA, 2022























VIRAL LOAD SUPPRESSION AMONG PEOPLE LIVING WITH HIV BY AGE AND SEX, SOUTH AFRICA, 2022























VIRAL LOAD SUPPRESSION (15 YEARS AND OLDER) LIVING WITH HIV BY SEX, RACE, AND AGE, SOUTH AFRICA, 2017 AND 2022

	2017		2022			
	n	%	95% CI	n	%	95% CI
Total	5 617	62.2	59.5-64.8	7 050	81.2	78.5-83.6
Sex						
Male	1 468	54.1	49.1-59.0	1 931	77.6	73.9-80.9
Female	4 149	66.9	64.3-69.5	5 117	82.9	79.8-85.7
Age group (years)						
15–24	736	47.7	40.9–54.6	614	70.1	63.3–76.1
25–49	3 874	61.7	58.3-64.9	4 621	80.5	76.6–83.9
15–49	4 610	60.0	57.2–62.8	5 235	79.5	75.9–82.7
15+	5 617	62.2	59.5-64.8	7 038	81.2	78.5-83.6



















95-95-95 INDICATOR DEFINITIONS



Diagnosed/know status if tested positive in the study and

🗦 Had self-reported being positive or

Tested positive for ART in the study or

Self-reported using ART



On ART

Tested positive for ARVs in the study

Self-reported using ART



Virally suppressed

<1000 copies/ml




















95-95-95 INDICATORS FOR PEOPLE AGED 15+ LIVING WITH HIV, SOUTH AFRICA, 2022






















CONDOM USE DURING MOST RECENT SEXUAL ENCOUNTER FOR PEOPLE WITH MULTIPLE SEXUAL PARTNERS*, SOUTH AFRICA, 2022



Age group (years)

















^{*} Who reported having 2 or more partners in past 12 months



CONCLUSIONS

- Promising decreases in HIV prevalence, coupled with high community VLS (81%), point to the impact of South Africa's National HIV Response, with support from the PEPFAR program
- Marked progress has been made towards South Africa's 95–95–95 adult treatment targets:
 - 90% of adults knew their status, 91% of those diagnosed were on ART, and 94% of those on ART were virally suppressed
 - Strategies to improve both HIV diagnosis and ART use are urgently needed to achieve the 2025 national goals.
- The HIV epidemic continues to disproportionately affect specific geographical regions and demographic groups, especially Black Africans and women
- SABBSM VI data will be used to target HIV programming to address the remaining gaps



















NEXT STEPS

- Finalise the main study report
- Complete the analysis for new HIV infections
- Produce summary sheets for provinces and selected districts



















CONSORTIUM AND PARTNERS

- U.S. Centers for Disease Control and Prevention (CDC)
- South African Medical Research Council (SAMRC)
- National Institute for Communicable Diseases (NICD)
- University of Cape Town (UCT)
- National Department of Health (NDoH)
- South African National AIDS Council (SANAC)
- United Nations Children's Fund (UNICEF)
- United States Agency for International Development (USAID)
- Joint United Nations Programme on HIV/AIDS (UNAIDS)



















FUNDING SOURCE

President's Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention (CDC).



















THANK YOU























LIST OF CONTRIBUTORS

Human Sciences Research Council		U.S. Centers for Disease Control and Prevention (CDC)		
Name	Role	Name	Role	
Prof Khangelani Zuma	Overall Principal Investigator	Dr Rachael Joseph	Co-Investigator	
Prof Leickness Simbayi	Principal Investigator	Dr Pelagia Murangandi	Co-investigator	
Dr Nompumelelo Zungu	Principal Investigator	Ms Nuha Naqvi	Co-investigator	
Prof Sizulu Moyo	Principal Investigator	South African Medical Research Council (SAMRC)		
Dr Edmore Marinda	Co-Principal Investigator	Name	Role	
Dr Sean Jooste	Co-Principal Investigator	Dr Tarylee Reddy	Statistician	
Dr Shandir Ramlagan	Project Director	Dr Nonhlanhla Yende-Zuma	Statistician	
Dr Musawenkosi Mabaso	Project Director	Ms Mikateko Mazinu	Statistician	
Dr Lehlogonolo Makola	Overall Project Manager	Ms Yusentha Balakrishna	Statistician	
Mr Johan Van Zyl	Project Manager: Quality Control	National Institute for Communicable Diseases (NICD)		
Dr Vuyelwa Mehlomakulu	Project Manager: HIV Testing Services	Name	Role	
Dr Rindidzani Magobo	Project Manager: Laboratory Testing	Prof. Adrian Puren	Co-Investigator	
Ms Yolande Shean	Communications Manager	Ms. Beverly Singh	Co-Investigator	
Mr Phaleng Maribe	Data Manager	Ms Ewalde Cutler	Co-Investigator	
Ms Goitseone Maseko	Statistician	Ms Zinhle Brukwe	Co-Investigator	
Ms Ronel Sewpaul	Statistician	University of Cape Town		
Dr Inbarani Naidoo	Co-Investigator	Prof Gary Maartens	Co-Investigator	
Dr Jeremiah Chikovore	Co-Investigator	Ms Sandra Castel	Co-Investigator	
Mr Adlai Davids	Co-Investigator			



Ms Mafanato Maluleke

Mr Lesiba Ofentse Molopa





Co-Investigator/Coordinator

Co-Investigator/Coordinator









